Neuren Pharmaceuticals Ltd (NEU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) has a cash flow conversion efficiency ratio of 0.397x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$128.31 Million ≈ $90.78 Million USD) by net assets (AU$323.27 Million ≈ $228.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NEU net asset quality index to measure how much of total assets are equity-financed.
Neuren Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Neuren Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Neuren Pharmaceuticals Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Neuren Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuren Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Klabin S.A
SA:KLBN3
|
0.058x |
|
Gas Malaysia Bhd
KLSE:5209
|
0.049x |
|
Lao Feng Xiang Co Ltd A
SHG:600612
|
-0.144x |
|
FLEX LNG Ltd
NYSE:FLNG
|
0.040x |
|
Fortress Income Fund Ltd
JSE:FFB
|
0.032x |
|
China Cinda Asset Management Co., Ltd.
F:0CI
|
N/A |
|
Robertet SA
PA:RBT
|
0.130x |
|
Corporate Travel Management Ltd
AU:CTD
|
0.010x |
Annual Cash Flow Conversion Efficiency for Neuren Pharmaceuticals Ltd (2002–2024)
The table below shows the annual cash flow conversion efficiency of Neuren Pharmaceuticals Ltd from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see NEU market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$363.90 Million ≈ $257.49 Million |
AU$-11.27 Million ≈ $-7.97 Million |
-0.031x | -103.44% |
| 2023-12-31 | AU$205.21 Million ≈ $145.20 Million |
AU$184.93 Million ≈ $130.85 Million |
0.901x | +941.36% |
| 2022-12-31 | AU$41.59 Million ≈ $29.43 Million |
AU$3.60 Million ≈ $2.55 Million |
0.087x | +134.07% |
| 2021-12-31 | AU$39.25 Million ≈ $27.77 Million |
AU$-9.97 Million ≈ $-7.05 Million |
-0.254x | +23.91% |
| 2020-12-31 | AU$24.20 Million ≈ $17.12 Million |
AU$-8.08 Million ≈ $-5.72 Million |
-0.334x | +60.56% |
| 2019-12-31 | AU$13.85 Million ≈ $9.80 Million |
AU$-11.72 Million ≈ $-8.29 Million |
-0.846x | -425.81% |
| 2018-12-31 | AU$24.67 Million ≈ $17.45 Million |
AU$6.41 Million ≈ $4.53 Million |
0.260x | +176.04% |
| 2017-12-31 | AU$16.36 Million ≈ $11.58 Million |
AU$-5.59 Million ≈ $-3.96 Million |
-0.342x | +88.46% |
| 2016-12-31 | AU$4.18 Million ≈ $2.96 Million |
AU$-12.38 Million ≈ $-8.76 Million |
-2.959x | -234.75% |
| 2015-12-31 | AU$14.40 Million ≈ $10.19 Million |
AU$-12.73 Million ≈ $-9.01 Million |
-0.884x | -163.10% |
| 2014-12-31 | AU$19.08 Million ≈ $13.50 Million |
AU$-6.41 Million ≈ $-4.54 Million |
-0.336x | -6.14% |
| 2013-12-31 | AU$24.36 Million ≈ $17.23 Million |
AU$-7.71 Million ≈ $-5.45 Million |
-0.317x | +31.96% |
| 2012-12-31 | AU$6.34 Million ≈ $4.49 Million |
AU$-2.95 Million ≈ $-2.09 Million |
-0.465x | -40.59% |
| 2011-12-31 | AU$9.45 Million ≈ $6.69 Million |
AU$-3.13 Million ≈ $-2.21 Million |
-0.331x | +59.31% |
| 2010-12-31 | AU$3.53 Million ≈ $2.50 Million |
AU$-2.87 Million ≈ $-2.03 Million |
-0.813x | -364.34% |
| 2009-12-31 | AU$7.35 Million ≈ $5.20 Million |
AU$-1.29 Million ≈ $-910.66K |
-0.175x | +89.20% |
| 2008-12-31 | AU$5.57 Million ≈ $3.94 Million |
AU$-9.04 Million ≈ $-6.40 Million |
-1.622x | -6.50% |
| 2007-12-31 | AU$7.55 Million ≈ $5.34 Million |
AU$-11.50 Million ≈ $-8.14 Million |
-1.523x | -169.10% |
| 2006-12-31 | AU$16.15 Million ≈ $11.42 Million |
AU$-9.14 Million ≈ $-6.47 Million |
-0.566x | -116.92% |
| 2005-12-31 | AU$32.16 Million ≈ $22.75 Million |
AU$-8.39 Million ≈ $-5.94 Million |
-0.261x | +37.81% |
| 2004-12-31 | AU$8.77 Million ≈ $6.20 Million |
AU$-3.68 Million ≈ $-2.60 Million |
-0.420x | -232.00% |
| 2003-12-31 | AU$-14.72 Million ≈ $-10.41 Million |
AU$-4.68 Million ≈ $-3.31 Million |
0.318x | +111.17% |
| 2002-12-31 | AU$1.82 Million ≈ $1.29 Million |
AU$-5.19 Million ≈ $-3.67 Million |
-2.846x | -- |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more